Abstract:Treatment regimens, especially in cancer, often include more than one medicine in order to achieve durable outcomes. Identifying the optimal combination of treatments has historically been done through clinical trial and error. And for many conditions, such as pancreatic cancer, an optimal treatment protocol has remained elusive, and the best available treatment combinations provide only modest benefit. Recent developments have led to the application of both experimental screening approaches and in silico modeling methods to identify synergistic drug combinations and expand the therapeutic options for multiple diseases. Here we conduct a study to compare different predictive approaches for identifying new treatment combinations for pancreatic cancer using cell line growth as an initial proxy for clinical utility. NCATS performed screening involving 496 pairwise combinations of 32 antineoplastic drugs, tested against the PANC-1 human pancreatic carcinoma cell line in duplicates using a 10 × 10 matrix format. This dataset served as the basis for generating and training advanced AI/ML models focused on pancreatic cancer. Next, three independent groups (NCATS, UNC and MIT), though in a collaborative manner, utilized three different workflows with AL/ML approaches to discover new perspective drug combinations against pancreatic cancer among over 1.5 million drug combinations. As a result of this collaboration, 88 proposed combinations were tested in a cell-based assay; 53 of them were synergistic (hit rate ~60%). While all machine learning approaches demonstrate advances in the direction of predicting synergistic drug combinations, graph convolutional networks resulted in the best performance with a hit rate ~83%, and Random Forest delivered the highest precision of 65%. Interestingly, all utilized AL/ML methods among the three groups proposed different drug combinations with a small overlap of only two combos from 90. This study demonstrates the potential of a collaborative modeling approach for prioritizing drug combinations in large-scale screening campaigns, particularly when focusing on maximizing the efficacy of drugs known to exhibit synergy.

Integrated Network Pharmacology Approach for Drug Combination Discovery: A Multi-Cancer Case Study

Network-based estimation of therapeutic efficacy and adverse reaction potential for prioritisation of anti-cancer drug combinations

DrugComboRanker: Drug Combination Discovery Based on Target Network Analysis

Predicting drug synergy using a network propagation inspired machine learning framework

Accelerating Complex Disease Treatment through Network Medicine and GenAI: A Case Study on Drug Repurposing for Breast Cancer

Prediction of Synergistic Anti-Cancer Drug Combinations Based on Drug Target Network and Drug Induced Gene Expression Profiles

Optimizing drug combination and mechanism analysis based on risk pathway crosstalk in pan cancer

Personalized Anti-Cancer Drug Combination Prediction by an Integrated Multi-level Network

Prediction of Synergistic Drug Combinations for Prostate Cancer by Transcriptomic and Network Characteristics

An Integrative Pharmacogenomic Approach Identifies Two-drug Combination Therapies for Personalized Cancer Medicine

Patient-Specific Network for Personalized Breast Cancer Therapy with Multi-Omics Data

In silico Genetic Network Models for *Pre-clinical Drug Prioritization

A network-based trans-omics approach for predicting synergistic drug combinations

Anticancer Target Combinations: Network-Informed Signaling-Based Approach to Discovery

Pre-Clinical Drug Prioritization Via Prognosis-Guided Genetic Interaction Networks

Harnessing machine learning to find synergistic combinations for FDA-approved cancer drugs

AI-driven discovery of synergistic drug combinations against pancreatic cancer

Network-informed discovery of multidrug combinations for ERα+/HER2-/PI3Kα-mutant breast cancer

Natural product based anticancer drug combination discovery assisted by deep learning and network analysis

SynergyX: a multi-modality mutual attention network for interpretable drug synergy prediction

Systems Pharmacology-Based Precision Therapy and Drug Combination Discovery for Breast Cancer